Mark A. Morgan

Hospital of the University of Pennsylvania

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 5 papers. Top paper: “Tumor-infiltrating nerves create an electro-physiologically active microenvironment and contribute to treatment resistance”.

Tumor-infiltrating nerves create an electro-physiologically active microenvironment and contribute to treatment resistance

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.04.24.058594

N/A

0.373DataRank · unranked

11 citations

Daniel W. Vermeer, Marianna Madeo, Hunter D. Reavis, Samuel J. Vermeer, Caitlin S. Williamson +23 more

H2Bub1 loss is an early contributor to clear cell ovarian cancer progression

JCI Insight(2023)10.1172/jci.insight.164995

N/A

0.312DataRank · unranked

7 citations

Priyanka Rawat, Hannah S. Rendulich, Akshaya V. Annapragada, Yasuto Kinose, Xiaoming Zhang +11 more

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

Gynecologic Oncology(2021)10.1016/j.ygyno.2021.08.024

N/A

0DataRank · unranked

117 citations

Stephanie L. Wethington, Cheyenne Pagan, Nawar Latif, János L. Tanyi, Lainie P. Martin +17 more

C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2444

N/A

0DataRank · unranked

79 citations

Payal D. Shah, Lainie P. Martin, János L. Tanyi, Nawar Latif, Mark A. Morgan +14 more

Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

10.1158/1078-0432.23814207.v1

N/A

0DataRank · unranked

0 citations

Payal D. Shah, Lainie P. Martin, János L. Tanyi, Nawar Latif, Mark A. Morgan +14 more